Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31363714 | 1.00 | GPR35 (0.56) | GPR35ALDH1A1HPGDTDP1HSD17B10 | |
| SCHEMBL445240 | 0.85 | ALDH1A1 (0.56) | GPR35ALDH1A1HPGDTDP1HSD17B10 | |
| SCHEMBL18535802 | 0.83 | GPR35 (0.50) | GPR35ALDH1A1HPGDTDP1HSD17B10 | |
| SCHEMBL6222813 | 0.82 | TSHR (0.55) | GPR35ALDH1A1HPGDTDP1ALOX15 | |
| SCHEMBL6823350 | 0.81 | GPR35 (0.56) | GPR35ALDH1A1HPGDTDP1ALOX15 | |
| SCHEMBL1024910 | 0.81 | GPR35 (0.56) | GPR35ALDH1A1HPGDTDP1ALOX15 | |
| SCHEMBL6640596 | 0.81 | MAPT (0.55) | GPR35ALDH1A1HPGDTDP1HSD17B10 | |
| SCHEMBL12384891 | 0.79 | MAPK1 (0.47) | GPR35ALDH1A1HPGDTDP1MAPK1 | |
| SCHEMBL18356979 | 0.79 | ALDH1A1 (0.47) | GPR35ALDH1A1HPGDTDP1HSD17B10 | |
| SCHEMBL29837063 | 0.79 | ALDH1A1 (0.47) | GPR35ALDH1A1HPGDTDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170281612-A1 | Methods for the Treatment of Cystic Fibrosis | NIVALIS THERAPEUTICS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281612-A1 | Methods for the Treatment of Cystic Fibrosis | NIVALIS THERAPEUTICS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-2274983-B1 | HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-05-31 | — | — | EP | disclosed |
| EP-2274983-B1 | HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-08-04 | — | — | US | disclosed |
| US-9315462-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-1449834-A2 | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | Bayer Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | disclosed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | disclosed |
| CN-1283180-A | Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
| EP-1049664-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | Bayer Corporation (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032436-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| US-4367235-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1983-01-04 | — | — | US | disclosed |
| EP-0000784-A1 | 4-Hydroxy-2-benzimidazolinone derivatives, process for their preparation and their use in medicaments | Roche Diagnostics GmbH (DE) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | GPR35 1728/4885ALDH1A1 290/4885HPGD 89/4885 |
| US-20170281612-A1 | Methods for the Treatment of Cystic Fibrosis | GSR, CBS, CTH | GPR35 1074/4885ALDH1A1 465/4885HPGD 101/4885 |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | MAP2K2, MAPK1, MAP2K1 | GPR35 2729/4885ALDH1A1 1875/4885HPGD 1118/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | GPR35 523/4885ALDH1A1 600/4885HPGD 1809/4885 |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | GPR35 1728/4885ALDH1A1 290/4885HPGD 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.